MacroGenics Stock (NASDAQ:MGNX)


ForecastChart

Previous Close

$1.18

52W Range

$0.99 - $16.59

50D Avg

$2.00

200D Avg

$3.24

Market Cap

$79.49M

Avg Vol (3M)

$778.01K

Beta

2.23

Div Yield

-

MGNX Company Profile


MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

341

IPO Date

Oct 10, 2013

Website

MGNX Performance


Latest Earnings Call Transcripts


Q2 22Aug 08, 22 | 11:05 PM
Q1 22May 03, 22 | 11:22 PM
Q4 21Feb 24, 22 | 8:54 PM

Peer Comparison


TickerCompany
NGMNGM Biopharmaceuticals, Inc.
PTGXProtagonist Therapeutics, Inc.
MLYSMineralys Therapeutics, Inc.
SNDXSyndax Pharmaceuticals, Inc.
KZRKezar Life Sciences, Inc.
ZNTLZentalis Pharmaceuticals, Inc.
MOLNMolecular Partners AG